FAQs
Most frequent questions and answers
The TriNetra™-Triumph test is a blood-based, multi-cancer early detection test that indicates the likely presence of 50 types of solid organ cancers across all stages. Not all tumors may be detected in the blood by the TriNetra™-Triumph test, nor does it diagnose cancer.
TriNetra™-Triumph evaluates blood samples to detect ‘Circulating Tumor Cells (CTCs)’. These CTCs are cancer cells that escape from the tumor and enter the bloodstream. TriNetra™-Triumph test enriches these CTCs present in the blood sample and confirms their identity using the ‘Immunocytochemistry’ (ICC) technique. If CTCs are detected, it indicates the likely presence of underlying solid organ cancer. If CTCs are not detected it indicates a lower risk of the presence of cancer.
The TriNetra™-Triumph is a prescription-based test which is indicated for asymptomatic individuals with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have a prior history of cancer. The TriNetra™-Triumph test is intended to be used in addition to, and not replace, other cancer screening tests recommended by your healthcare provider.
Family history is only one of many risk factors associated with cancer development. Other risk factors include age, eating habits, lifestyle, living or working environment, genetics, and many others. Please consult your healthcare provider to determine whether the TriNetra™-Triumph test is right for you.
The TriNetra™-Triumph test has been validated for the evaluation of the risk of the presence of various types of solid organ cancers like adenocarcinoma, squamous cell carcinoma, hepatocellular, renal cell, and transitional cell carcinoma. The CTC-based multi-organ screening tests performed using Datar Cancer Genetics’ technology have shown sensitivity of 88.24% for detection and localization of solid organ malignancies, while specificity of 96.3% was observed in asymptomatic individuals and specificity of 95% was observed in individuals with benign tumors.
We are happy to share the details of the TriNetra™-Triumph test with you and/or your healthcare provider. You can write to us at [email protected] for the details.
The TriNetra™-Triumph test being new to the market is not presently covered by insurance.
The TriNetra™-Triumph test doesn’t require any kind of preparation or fasting.
Approximately 20 mL of whole blood is required for the TriNetra™-Triumph test.
Please get in touch with your healthcare provider to cancel your TriNetra™-Triumph findings if you no longer want to receive them. Please be aware that the company will not refund any test fees for cancelled tests.
Your result will be made available to your healthcare provider within 12 business days from the time the sample is received in our UK laboratory.
This means there is a higher risk of the presence of solid organ cancer, but this is not a confirmed cancer diagnosis. The TriNetra™-Triumph test can indicate where in the body cancer may be coming from to help your healthcare provider guide the next steps. Your healthcare provider will discuss appropriate follow-up testing to confirm if cancer is present.
This means that the TriNetra™-Triumph test did not detect Circulating Tumor cells (CTCs) as evaluated by immunocytochemistry analysis, which is suggestive of a lower risk of the presence of cancer. Please be mindful that the TriNetra™-Triumph report does not completely rule out the presence of cancer as some cancers may not shed detectable tumor cells in the blood.
Individuals should be advised to continue participating in all recommended cancer screening options at appropriate intervals. Missing routine screenings or ignoring symptoms can lead to a delayed diagnosis of cancer. If any signs and symptoms arise, timely clinical evaluation by qualified healthcare professionals is recommended.
Cancer is a broad term for a very serious disease in which cells in a part of the body start growing in an uncontrolled manner, form lumps in a way that is not normal, and then spread to other parts of the body.
Carcinoma is a cancer arising in the epithelial tissue or the lining of the internal solid organs or skin.
Sarcoma is a cancer that begins in the bones or soft tissues of the body.
Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control.
TriNetra™-Triumph is developed to detect various types of carcinomas, which are epithelial cancers originating in solid organs.
Not all cancers may be detected in the blood. When the TriNetra™-Triumph test indicates a higher risk of the presence of particular cancer due to the detection of CTCs, the finding must be confirmed by diagnostic tests in accordance with standard medical practice. For example, commonly recommended cancer screening tests such as colonoscopy or mammograms are routinely used for colon or breast cancer screening.
The TriNetra™-Triumph test is intended to be used in addition to and not replace standard-of-care screening tests and can help maximize the benefits of early cancer detection. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer. Ask your healthcare provider about what cancer screening tests are right for you.
Detection of CTCs using the TriNetra™-Triumph test indicates a higher risk of the presence of cancer. This test does not diagnose cancer. You need to consult your healthcare provider for additional diagnostic tests to confirm the presence of cancer.
Your healthcare provider is the best person to determine when to take the TriNetra™-Triumph test again. However, the TriNetra™-Triumph test can be performed annually as a part of your routine screening test.
We will email the results/report of the TriNetra™-Triumph test to the healthcare provider who ordered your test.